linjc16/ctgov huggingface dataset:
Postoperative VEGF and Recurrence After Colon Cancer Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to study the relationship between the angiogenic response to surgical aggression, determined through the serum levels of vascular endothelial growth factor (VEGF) on postoperative day four, and the tumor recurrence in patients with colon cancer operated with a curative intention.

Detailed Description
-----------------
DESIGN: Prospective multicentric study. PARTICIPATION: Colorectal Surgery Units of Hospital del Mar, Barcelona; Hospital Universitari Joan XXIII, Tarragona; Hospital Universitari La Fe, Valencia; Hospital Clínico San Carlos, Madrid; Hospital General de Granollers, Granollers; Hospital Germans Trias i Pujol, Badalona; Athalaia, Xarxa Assistencial Universitària de Manresa, Manresa STUDY SUBJECTS: 280 consecutive patients with non-metastatic colon cancer in whom a curative intent resection is performed. DETERMINATIONS: Determination of the proangiogenic cytokine VEGF in serum on the postoperative day four to assess its relationship with oncological results on long-term follow-up.

Official Title
-----------------
Postoperative Serum VEGF Concentration as an Independent Prognostic Factor for Recurrence After Curative Colon Cancer Surgery. Multicentric Study.

Conditions
-----------------
Surgery, Angiogenesis, Colon Cancer, Recurrence, VEGF Overexpression

Intervention / Treatment
-----------------
* Procedure: Surgery for colon cancer with intention to cure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, Patients who will undergo elective surgical resection with potentially curative intention Exclusion Criteria: Patients with metastatic disease Patients with synchronous colon neoplasia or in the previous five years Patients undergoing emergency surgery Patients who do not sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients after surgery for colon cancer with intention to cure<br>Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention | Procedure: Surgery for colon cancer with intention to cure<br>* Surgery by open or laparoscopic approach<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VEGF in serum on postop day 4 | A 10cc sample of peripheral blood will be drawn on postoperative day 4 | Postoperative day 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VEGF, Colon Cancer, Surgery, Recurrence
A Retrospective Study of the iTotal CR Knee Replacement System

Study Overview
=================
Brief Summary
-----------------
This study involves retrospective collection of data regarding the first approximately 100 iTotal Knee Replacement System surgeries and their short term outcomes at a small set of centers throughout the US.

Official Title
-----------------
A Retrospective, Multi-Center Study to Evaluate the ConforMIS iTotal® CR (Cruciate Retaining) Total Knee Replacement System

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Device: iTotal KRS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical condition included in the approved Indications For Use Has signed the informed consent form to allow review of medical records and collection of data therein. > 18 years of age Exclusion Criteria: Treatment with iTotal in a manner inconsistent with Instructions for Use Unwilling to sign then informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| iTotal KRS<br> | Device: iTotal KRS<br>* Total Knee Replacement System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Function | Range of Motion | Average of 7 months post-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Revision Rate | Number of knees that required a reoperation to remove/replace/add implant components | Average of 7 months | 
| Number of Transfusions | Number of knees that required a blood transfusion during the initial hospital stay post-operative | Initial hospital stay | 
| Manipulations Under Anesthesia | Number of knees that required a subsequent procedure to restore knee range of motion | Up to 7 months post-operative |
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients

Study Overview
=================
Brief Summary
-----------------
A Nasal Spray device containing Dead Sea minerals and plant extracts, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Detailed Description
-----------------
A Nasal Spray device containing Dead Sea minerals and plant extracts, designed to incur a PPAR-alpha agonistic effect, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Official Title
-----------------
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients

Conditions
-----------------
COVID-19 Infection

Intervention / Treatment
-----------------
* Device: Nasal Spray Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having tested positive to Covid-19 on PCR test - Exclusion Criteria: Pregnancy Low blood pressure On immune system suppressing medications -

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: A control group is allocated a placebo solution
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Patients treated with actual device with actual solution<br> | Device: Nasal Spray Device<br>* A Nasal Spray apparatus containing a liquid<br>|
| Placebo Comparator: Patients treated with actual device with placebo solution<br> | Device: Nasal Spray Device<br>* A Nasal Spray apparatus containing a liquid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Covid-19 infection self-testing on days 2, 4 following testing positive on PCR test | Testing using a self testing kit of the Quidel QuickView type | First 7 days after testing positive on PCR test | 
| Symptoms monitoring | Monitoring any disease symptoms reported by patient | First 7 days after testing positive on PCR test |
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Study Overview
=================
Brief Summary
-----------------
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. When children with primary Raynaud's Phenomenon are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. Children with primary Raynaud's Phenomenon have no underlying systemic disease. The cause for their symptoms is unknown. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of primary Raynaud's episodes in juvenile patients.

Conditions
-----------------
Raynaud's Disease

Intervention / Treatment
-----------------
* Drug: Pletal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion critera: 5 to 6 years old fulfill diagnostic criteria for primary or secondary Raynaud's

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pletal|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
circulatory, vascular, idiopathic
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

Study Overview
=================
Brief Summary
-----------------
Studies have shown that there is a significant association between serum bilirubin concentrations and risk of coronary artery disease (CAD). So far, no linkage analysis in humans between serum bilirubin and DNA markers has been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in serum bilirubin metabolism and bilirubin concentration. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in more than three hundred families. Serum bilirubin was measured in the first and second exams of the Framingham Offspring. These data provide us the opportunity to undertake linkage analyses to map QTL of serum bilirubin.

Detailed Description
-----------------
Many studies showed that there is a significant relationship between serum bilirubin levels and risk of coronary artery disease (CAD). We carried out a genome-wide scan for quantitative trait loci of serum bilirubin through the 330 extended Framingham families and found significant evidence of linkage of serum bilirubin to chromosome 2q telomere where an important candidate gene, Uridine diphosphate glycosyltransferase 1 gene (UGT1A1), resides. The purposes of this protocol are to confirm linkage between serum bilirubin and UGT1A1, mathematical modeling and association studies between the genotypes of UGT1A1 and CAD.

Official Title
-----------------
A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study

Conditions
-----------------
Genetics

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: The study population will include the members of the 330 Framingham Study families and 1888 random individuals. The Original Cohort will also be included.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetics, Population, CHD Risk, Epidemiology, Gene Mapping
Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment

Study Overview
=================
Brief Summary
-----------------
Comparing primary PPV with 360° endolaser photocoagulation with primary PPV with an encircling band for patients with RRDs.

Detailed Description
-----------------
published

Official Title
-----------------
Primary Vitrectomy Combined With 360° Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment (V.E.E. Study)

Conditions
-----------------
Rhegmatogenous Retinal Detachment, Primary Vitrectomy, Encircling Band, Endolaser Treatment

Intervention / Treatment
-----------------
* Procedure: Encircling Band
* Procedure: Endolaser Photocoagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary rhegmatogenous retinal detachment with or without macula-off detachment phakic or pseudophakic eyes Multiple breaks, inferior and posterior located breaks or unclear hole formation Proliferative vitreoretinopathy (PVR) stage A and B Exclusion Criteria: Previous retinal detachment surgery Giant tears PVR stage C Age less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br> | Procedure: Encircling Band<br>* ppVE and encircling band<br>|
| Active Comparator: Group 2<br> | Procedure: Endolaser Photocoagulation<br>* ppVE and endolaser photocoagulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal redetachment rate |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgery-related complications, patients' comfort, refractive change, visual acuity and optical coherence tomography. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rhegmatogenous retinal detachment, primary vitrectomy, encircling band, endolaser treatment
Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Study Overview
=================
Brief Summary
-----------------
To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as measured by p24 antigen levels. Effect on relative HIV infectivity.

Official Title
-----------------
Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Fat Emulsion 2%
* Drug: Fat Emulsion 20%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Zidovudine (AZT). All drugs used for the standard treatment of opportunistic infections. Other drugs used for the treatment of other AIDS conditions if they have been started more than 3 months prior to study entry. Patients must have: Diagnosis of AIDS. Weight loss of > 10 percent premorbid body weight. Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma. Require home total parenteral nutrition (TPN) for a period of approximately 3 months. Life expectancy = or > 90 days. Prior Medication: Allowed: Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Patients with the following are excluded: Life expectancy < 90 days. Biliary stasis. History of drug abuse. Prior Medication: Excluded within 3 months of study entry: Immunomodulators. Experimental antiviral DT. History of drug abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fat Emulsion 2%|nan|
|Drug: Fat Emulsion 20%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liposyn, Weight Loss, Parenteral Nutrition, Total, AIDS-Related Opportunistic Infections, Acquired Immunodeficiency Syndrome
A Prospective Trial for the Effectiveness of the Use of Spinal Cord Stimulation (SCS) in Failed Knee Surgery

Study Overview
=================
Brief Summary
-----------------
A study for patients who have chronic postoperative pain who had knee replacement surgery. If qualified, a 14 day trial and an implantation of spinal cord stimulator for control of pain will be administered. This study will evaluate effectiveness of pain control. Subjects will be followed for one year post implantation.

Detailed Description
-----------------
Male and Female over the age of 18 who have had a total knee replacement at least nine months ago. Continue with unilateral knee pain equal to or greater than 4 on a 1 to 10 scale. Subjects will receive a trial placement of spinal cord stimulator for 5 to 10 days. if trial is successful subjects will proceed to permanent placement of stimulator for the treatment of the knee pain. subjects will then be followed post implant to assess the effectiveness of the stimulator for the pain.

Official Title
-----------------
A Prospective Single Centre Open Label Trial to Assess the Effectiveness of the Use of Spinal Cord Stimulation in Subjects With Chronic Knee Pain Failed Knee Surgery

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Device: Spinal cord stimulator (Boston Scientific)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 18 years old total knee replacement at least nine months prior to enrollment unilateral knee pain at least 4 or more on a 1-10 visual analog scale failed other conservative treatments - Exclusion Criteria: life expectancy of at least 6 months significant disease including Complex Regional Pain Syndrome,ipsilateral radiculopathy presence of pacemaker/vns or other Spinal Cord Stimulator previous lumbar surgery active infection unable to hold anticoagulants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Visual Analog Scale | standardized visual pain scale | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health Related Quality of Life | Health Related Quality of Life standardized questionaire | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic pain from failed knee surgery
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Study Overview
=================
Brief Summary
-----------------
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.

Detailed Description
-----------------
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases, validate accuracy, specificity and sensitivity of Hsp90α kit.

Official Title
-----------------
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Conditions
-----------------
Liver Cancer

Intervention / Treatment
-----------------
* Device: hsp90


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cancer patients Healthy volunteers, Benign liver diseases patients Exclusion Criteria: Patients who Previously accepted radiotherapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: liver cancer<br>Detect plasma Hsp90α concentration of liver cancer patients | Device: hsp90<br>* Detect plasma Hsp90α concentration of lung cancer patients<br>* Other names: biomarker;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hsp90α Concentration of plasma | Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit | 4 months |